...
首页> 外文期刊>Turkderm : >Oral Mirtazapine in Persistent Chronic Urticaria
【24h】

Oral Mirtazapine in Persistent Chronic Urticaria

机译:持久性荨麻疹的口服米氮平

获取原文
           

摘要

Chronic urticaria accounts for up to 75% of patients with urticaria attending dermatology clinics and can persist for many years. Chronic urticaria often causes significant quality of life issues due to pruritus and urticarial lesions resistant to treatment. Patients attending urticaria clinics have a similar impairment of quality of life as those with eczema or those with coronary disease awaiting by pass surgery. A good response to standard treatment with oral H1 receptor antagonists occurs in under 50%. Immunomodulatory or immunosuppression therapy might therefore required in patients with severe refractory chronic urticaria. But these treatments have too many adverse effects and difficulties in their using. In two current reports, three cases of severe chronic urticaria, unresponsive to conventional therapy, with a successful response to antidepressant mirtazapine were presented. Herein we present three cases responding oral mirtazapine, resistant combination therapies including antihistaminics, leucotrien antagonists and systemic corticosteroids. (Turkderm 2008; 42: 31-3)
机译:在皮肤科诊所就诊的荨麻疹患者中,慢性荨麻疹最多占75%,并且可以持续多年。慢性荨麻疹通常由于对治疗具有抵抗性的瘙痒和荨麻疹病变而引起重大的生活质量问题。荨麻疹诊所的患者的生活质量与湿疹患者或通过通行手术等待的冠心病患者相似。口服H1受体拮抗剂对标准治疗的良好反应发生率低于50%。因此,对于重度难治性慢性荨麻疹患者可能需要进行免疫调节或免疫抑制治疗。但是这些治疗方法有太多的副作用和使用困难。在目前的两份报告中,介绍了三例严重的慢性荨麻疹患者,他们对常规疗法无反应,并且对抗抑郁药米氮平具有成功的反应。在本文中,我们介绍了三例口服米氮平,口服抗组胺药,白三烯拮抗剂和全身性皮质类固醇耐药的联合疗法。 (Turkderm 2008; 42:31-3)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号